People’s behaviour has a major role in the success of test, trace and isolate programmes. Uncertainty about whether to report symptoms, low perceived risk of COVID-19 disease and concerns about the consequences of self-isolation are among the barriers to adherence. Has the Scientific Advisory Group for Emergencies looked at adherence to TTI? What evidence is there on people’s understanding and willingness to be tested, provide contact details and self-isolate? Is there anything that can be done to improve this?

  • Rapid response

    Test, trace and isolate programmes across the UK are under pressure as COVID-19 cases rise in all age groups and demand for tests grows. Further pressure comes from people seeking tests because they have symptoms caused by other respiratory viruses but need a test in order to rule out COVID-19. The Scientific Advisory Group on Emergencies has described the impact of current test and tracing on the transmission of the virus as “marginal”. How does test and trace work and what are the current challenges limiting its effectiveness in reducing COVID-19 cases?

  • Rapid response

    There is emerging evidence that COVID-19 affects many systems of the body, with patients reporting a wide range of symptoms. ‘Long-haulers’ are patients who experience ongoing COVID-19 symptoms for several months after infection. These include fatigue, difficulties in thinking, shortness of breath, chest pain, irregular or abnormal heart rhythm, and joint pain. 

  • Rapid response

    The latest research suggests that antibodies can be detected in recovered patients for up to 2 to 3 months after symptoms. There's also emerging evidence for the role of T cells in the immune response. A better understanding of the immune response is vital if there is going to be a successful vaccine.

  • Rapid response

    There are almost 150 coronavirus vaccine candidates under development. Only 19 of these are now being tested in humans. Many types of vaccines are rapidly progressing through clinical trials. Only two vaccine candidates have announced large scale Phase 3 trials, involving several thousands of people. Only one candidate has been approved for restricted human use. Measuring a reduction in COVID-19 levels is an obstacle for Phase 3 clinical trials, as they require a high infection rate among the tested population to prove vaccine efficacy. International agreements with countries where SARS-CoV-2 infection rates are still high are facilitating those trials. Future challenges in vaccine development include a better understanding of COVID-19 immunity and development of vaccination strategies.